Jason Mouabbi, MD

Explore oral treatment choices after CDK4/6 progression in ER+ metastatic breast cancer, using ESR1/PIK3CA ctDNA plus scans and markers to track response.

New data highlight oral SERD combination therapies boosting progression-free survival, while raising toxicity and reshaping when ESR1 mutation testing guides treatment choices.

Experts compare oral SERDs’ side effects, quality-of-life gains, and why brief ESR1 testing delays help choose smarter ER+ breast cancer therapy.

Expert guidance on post-CDK4/6 metastatic breast cancer care, using liquid biopsy mutations to tailor oral SERDs versus targeted doublets for best outcomes.

Oral SERDs transform metastatic breast cancer care, with elacestrant boosting outcomes in ESR1-mutant disease and showing strong real-world progression-free survival.

Why ESR1 mutations rise after CDK4/6 therapy, when to retest via liquid biopsy, and how low VAF still guides SERD choices.

Experts discuss the potential of antibody-drug conjugates in treating triple-negative breast cancer, highlighting ongoing trials and emerging therapies.

Experts discuss the critical unmet needs in triple-negative breast cancer, highlighting innovative treatments and the importance of developing effective biomarkers.

Explore effective strategies for managing side effects of ADC therapy in triple-negative breast cancer, focusing on toxicity and patient care.

This segment emphasizes the need to ensure equitable access to novel HER2-targeted therapies through financial and logistical support, accurate biomarker testing, and effective knowledge dissemination to community clinicians.

This segment emphasizes that multidisciplinary collaboration and survivorship planning are essential to safely deliver HER2-targeted therapies and support long-term patient outcomes.

Clinicians show how to tailor HER2 treatment beyond guidelines, using proactive education and monitoring to curb ADC/TKI toxicities.

Infusion bottlenecks, prior authorizations and travel barriers limit access to new HER2 therapies; upcoming trials test better sequencing and equity.

Experts weigh HER2+ metastatic options after T‑DXd, balancing tucatinib CNS benefit, ADC‑after‑ADC evidence, and patient toxicity or comorbidities.

Experts weigh how early HER2 escalation with T‑DXd reshapes metastatic sequencing, with tucatinib options and APHINITY’s long-term signals.

Experts unpack second-line HER2+ breast cancer choices, why T-DXd leads, and when T-DM1 or tucatinib matters—especially with brain mets.

Experts discuss the sequencing of antibody-drug conjugates in breast cancer treatment, exploring optimal strategies and emerging clinical data.

Explore the promising role of trastuzumab deruxtecan in treating HER2-low triple-negative breast cancer, highlighting key trial findings and expert insights.

In this segment, Dr. Jason Mouabbi and Dr. Bardia explore the growing importance of ESR1 mutations in the management of ER-positive, HER2-negative metastatic breast cancer, particularly after progression on CDK4/6 inhibitor–based therapy.

Dr. Aditya Bardia provides an overview of the current standard of care in the first-line setting, emphasizing the established role of endocrine therapy combined with CDK4/6 inhibitors.

It seems there is no text provided for summarization. Please share the content you'd like summarized, and I'll be happy to help!

Dr. Tarantino discusses the promising results of the Trodelvy breast cancer study, highlighting its impact on treatment for high-risk patients.

Dr. Yuan discusses the ASCENT-03 trial's efficacy, crossover implications, and safety data for sacituzumab govitecan in cancer treatment.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Explore the latest advancements in clinical trials for early-stage triple-negative breast cancer, focusing on promising antibody-drug conjugates (ADCs).

Discover the promising advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative and hormone-positive breast cancer.

Explore the evolving treatment landscape for early-stage triple-negative breast cancer, highlighting innovative therapies and clinical trial insights.

Jason Aboudi Mouabbi, MD, discussed the importance of using ctDNA testing to inform treatment decision-making across breast cancer populations.

Explore the evolving treatment landscape for early-stage triple-negative breast cancer, highlighting innovative therapies and clinical trial insights.